Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages

Who May Qualify: - Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV) - Age 50 years or older at the time of SMH diagnosis - Caucasian ethnicity - SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea) - SMH dimensions equal to or greater than one papillary diameter - Pneumatic displacement treatment performed within 36 hours of SMH diagnosis Who Should NOT Join This Trial: - SMH estimated to be present for more than 15 days at the time of diagnosis - SMH secondary to conditions other than MNV - Presence of proliferative diabetic retinopathy in the study eye - Aphakia in the study eye - Inadequate pupillary dilation, media opacities, or other impediments to retinal imaging - Previous pneumatic displacement procedures for SMH in the study eye - Ocular surgery in the 8 weeks preceding the pneumatic displacement intervention - Follow-up duration of less than 6 months following the procedure Always talk to your doctor about whether this trial is right for you.